| 产品名称： | Clone 15 HL-60 |
|---|---|
| 商品货号： | TS212344 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute promyelocytic leukemia |
| Age： | 36 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Clone 15 was established in 1984 from a clone of HL-60 (ATCC CCL-240) that had been grown at an elevated pH (pH 7.6 to 7.8) for 2 months. |
| Clinical Data： | 36 years Caucasian female |
| Receptor Expression： | complement, expressed Fc, expressed interleukin 5 (IL-5), expressed |
| Genes Expressed： | eosinophil granule proteins: eosinophil major basic protein (MBP), eosinophil peroxidase (EPO), eosinophil cationic protein (ECP) and eosinophil derived neurotoxin (EDN) |
| Cellular Products： | eosinophil granule proteins: eosinophil major basic protein (MBP), eosinophil peroxidase (EPO), eosinophil cationic protein (ECP) and eosinophil derived neurotoxin (EDN) |
| Comments： | This clone, picked from soft agar, was selected for its ability to undergo eosinophilic differentiation when treated with butyric acid. Initially, 80% of the treated cells will differentiate as eosinophils. However, with continued passage the line will gradually exhibit a modest degree of reversion such that a higher percentage of the cells will exhibit neutrophilic differentiation. The cells express IL-5 receptors and eosinophil granule proteins, and exhibit chemotaxis to eosinophil specific eosinophilotactins. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition or replacement of medium. Start new cultures at 2 X 105 viable cells/mL and subculture at 1 X 106 cells/mL. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 13,14 D13S317: 8,11 D16S539: 11 D5S818: 12 D7S820: 11,12 THO1: 7,8 TPOX: 8,11 vWA: 16 |
| Name of Depositor： | S Fischkoff |
| Deposited As： | Homo sapiens |
| Year of Origin： | 1984 |
| References： | Fischkoff SA. Graded increase in probability of eosinophilic differentiation of HL-60 promyelocytic leukemia cells induced by culture under alkaline conditions. Leuk. Res. 12: 679-696, 1988. PubMed: 3184985 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Clone 15 HL-60 |
|---|---|
| 商品货号： | TS212344 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute promyelocytic leukemia |
| Age： | 36 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Clone 15 was established in 1984 from a clone of HL-60 (ATCC CCL-240) that had been grown at an elevated pH (pH 7.6 to 7.8) for 2 months. |
| Clinical Data： | 36 years Caucasian female |
| Receptor Expression： | complement, expressed Fc, expressed interleukin 5 (IL-5), expressed |
| Genes Expressed： | eosinophil granule proteins: eosinophil major basic protein (MBP), eosinophil peroxidase (EPO), eosinophil cationic protein (ECP) and eosinophil derived neurotoxin (EDN) |
| Cellular Products： | eosinophil granule proteins: eosinophil major basic protein (MBP), eosinophil peroxidase (EPO), eosinophil cationic protein (ECP) and eosinophil derived neurotoxin (EDN) |
| Comments： | This clone, picked from soft agar, was selected for its ability to undergo eosinophilic differentiation when treated with butyric acid. Initially, 80% of the treated cells will differentiate as eosinophils. However, with continued passage the line will gradually exhibit a modest degree of reversion such that a higher percentage of the cells will exhibit neutrophilic differentiation. The cells express IL-5 receptors and eosinophil granule proteins, and exhibit chemotaxis to eosinophil specific eosinophilotactins. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition or replacement of medium. Start new cultures at 2 X 105 viable cells/mL and subculture at 1 X 106 cells/mL. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 13,14 D13S317: 8,11 D16S539: 11 D5S818: 12 D7S820: 11,12 THO1: 7,8 TPOX: 8,11 vWA: 16 |
| Name of Depositor： | S Fischkoff |
| Deposited As： | Homo sapiens |
| Year of Origin： | 1984 |
| References： | Fischkoff SA. Graded increase in probability of eosinophilic differentiation of HL-60 promyelocytic leukemia cells induced by culture under alkaline conditions. Leuk. Res. 12: 679-696, 1988. PubMed: 3184985 |
